Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6984832 | 1.00 | ALDH1A1 (0.52) | ALDH1A1RAB9AKMT2AMEN1CYP1A2 | |
| SCHEMBL6980418 | 0.79 | FDPS (0.64) | ALDH1A1KMT2AMEN1HPGDFDPS | |
| SCHEMBL3531876 | 0.79 | ALDH1A1 (0.46) | ALDH1A1HPGDFDPSMAOBLMNA | |
| SCHEMBL6980423 | 0.79 | FDPS (0.64) | ALDH1A1KMT2AMEN1HPGDFDPS | |
| SCHEMBL15711568 | 0.76 | ESR1 (0.45) | ALDH1A1KMT2AMEN1CYP3A4FDPS | |
| SCHEMBL6986648 | 0.74 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL13470060 | 0.74 | TTR (0.57) | ALDH1A1CYP3A4HPGDMAOBTDP1 | |
| SCHEMBL24711757 | 0.73 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL3534060 | 0.73 | CYP1A2 (0.46) | ALDH1A1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL8482189 | 0.73 | MAPT (0.49) | ALDH1A1RAB9ACYP3A4MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1292585-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001098282-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | SQLE, CYP17A1, ACOX1 | ALDH1A1 1026/4885RAB9A 3825/4885KMT2A 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.